Its specific anti-tumour mechanism is as follows: (1) Antibody-dependent cellular cytotoxicity (ADCC): The Fc fragment of rituximab can bind to the Fc receptors of various effector cells (macrophages, T cells, NK cells, etc.)and activate effector cells to lose the cytotoxic perforin and granase, thus mediating antibody-dependent cytotoxicity [21]. Here, PRF1 is linked to neoplasm.